Compare AMRX & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMRX | OBDC |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.6B |
| IPO Year | 2018 | 2015 |
| Metric | AMRX | OBDC |
|---|---|---|
| Price | $17.94 | $11.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $15.60 | $14.00 |
| AVG Volume (30 Days) | 1.8M | ★ 4.3M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 13.40% |
| EPS Growth | ★ 157.89 | N/A |
| EPS | ★ 0.37 | 0.08 |
| Revenue | N/A | N/A |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | ★ $48.95 | $141.63 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.20 | $10.52 |
| 52 Week High | $19.26 | $14.44 |
| Indicator | AMRX | OBDC |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 53.68 |
| Support Level | $16.61 | $11.06 |
| Resistance Level | $18.13 | $11.92 |
| Average True Range (ATR) | 0.67 | 0.25 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 48.32 | 51.50 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.